Wolfe Research Initiates Coverage On Harmony Biosciences Hldgs with Outperform Rating, Announces Price Target of $60

Benzinga Newsdesk www.benzinga.com Positive 84.2%

Neg 0% Neu 0% Pos 84.2%

Wolfe Research analyst Rudy Li initiates coverage on Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Outperform rating and announces Price Target of $60.